Opens profile photo
Follow
Click to Follow nathanvardi
Nathan Vardi
@nathanvardi
I am Managing Editor for Enterprise . Author of For Blood And Money shorturl.at/ryRXY
New YorkJoined February 2011

Nathan Vardi’s Tweets

Pinned Tweet
🚨Publication day for my book, FOR BLOOD AND MONEY: BILLIONAIRES, BIOTECH AND THE QUEST FOR A BLOCKBUSTER DRUG🚨 It’s about the development of two rival cancer drugs that made a difference, and the crazy golden age of biotechnology. Order here:
4
48
The greatest trade in the history of Wall Street was a short. And the man who did it almost lost it all by going long everything from banks to gold miners.
Quote Tweet
The moral of the story: Short selling is not a good way to make money, but it does make for good documentaries (Please watch Betting on Zero). We no longer short stocks, but we have a lot of respect for short sellers who do good research like @HindenburgRes
Show this thread
3
Thanks and for having me on the best investing podcast out there to talk about FOR BLOOD AND MONEY. Calling it now, the only book tour stop that will end with tequila seltzers.
Quote Tweet
TCAF 78 is out now on all podcast platforms‼️⏯️ @nathanvardi joins @Downtown and @michaelbatnick to discuss Nathan's book (For Blood and Money), the biotech landscape, the GOAT of investing, and much more!🔥 🎙️Apple: buff.ly/3HfXIrh 🎙️Spotify: buff.ly/40bov0n
Image
Image
Image
4
25
Thanks for the nice Sunday 🧵 about FOR BLOOD AND MONEY. You hit many of the key themes I was thinking about when I was writing and reporting the book.
Quote Tweet
Adding my praise for and recommendation of @nathanvardi’s For Blood and Money. Not only highly educational for biotech historians but also a fun and engaging read for anyone with an interest in science and medicine (1/10)
Show this thread
2
Just want to clarify $BGNE did not submit PFS data as part of its Brukinsa CLL submission package. It likely will in the future. I should have been more careful.
Quote Tweet
For those interested in FOR BLOOD AND MONEY, $BGNE Brukinsa CLL approval this week did not get superior PFS on its label vs Imbruvica. Only ORR superiority. Shows difference between press release data and how regulators view it.
1
3
For those interested in FOR BLOOD AND MONEY, $BGNE Brukinsa CLL approval this week did not get superior PFS on its label vs Imbruvica. Only ORR superiority. Shows difference between press release data and how regulators view it.
1
2
Thanks and for having me on biotech's best pod to talk about FOR BLOOD AND MONEY.
Quote Tweet
This week's podcast: We talked to @nathanvardi about his new biotech book, "For Blood and Money." We asked him: How much greed, resentment, lust for power and ego is required to develop blockbuster cancer drugs? In the amazing story he tells: A lot! statnews.com/2023/01/19/pod
Show this thread
2
4
Here's a thoughtful and sincere reaction to FOR BLOOD AND MONEY. So pleased the book is making this kind of connection with readers. Thanks, Matt.
Quote Tweet
#Business #Books "For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug" @nathanvardi My only initial skepticism was emotional, having, like too many, fairly recently lost a loved one to #cancer (albeit not blood cancer). But goodness, what a read (1/7
Show this thread
Image
1
8
The ROI of buying a multibillion-dollar cancer drug for $1,000 is pretty high. So glad you enjoyed FOR BLOOD AND MONEY, Kyle.
Quote Tweet
fascinating read about the R&D saga behind two big cancer drugs Scientology! $1,000 to acquire a drug candidate?! Modeling a drug name (ibrutinib/Imbruvica) after iPhone/iPad branding. my fave line: “we’ll make new mistakes” @nathanvardi
Image
Image
1
So glad you liked FOR BLOOD AND MONEY, Adam. But I know that won't stop you from asking me hard-hitting questions on the Readout LOUD next week. I'll be ready.
Quote Tweet
I read “For Blood and Money” by @nathanvardi on the flight home y’day. Bob Duggan, Wayne Rothbaum, Scientology, BTK inhibitors, Pharmacylics, Acerta. Eye candy for any biotech fan. Highly recommend. Nathan will be our guest on the Readout LOUD next week.
Image
5
I was so pumped when Barry Werth sent me a great promotional blurb for FOR BLOOD AND MONEY. He set the standard for this kind of genre.
Quote Tweet
Haven’t read this yet, but seeing lots of positive comments from smart biotech folks — looking forward to digging in and hearing @nathanvardi on the STAT podcast. Possible contender for “biotech must-read” list alongside Billion $ Molecule, etc.? twitter.com/adamfeuerstein…
1
2
Here's a nice 🧵 from , who I write about in FOR BLOOD AND MONEY. He's made such enormous contributions, always with patients in mind. Great guy.
Quote Tweet
BTK inhibitors have transformed the lives of many patients with Chronic Lymphocytic Leukemia and other lymphomas. These drugs "exploded" onto the scene in 2013-2014 and have fundamentally changed the way we treat the disease. What many people don't know is how it all happened..
Show this thread
6
INFLATION WATCH: Cost of living fell 0.1% in December, CPI shows. Matches forecast. First drop since May 2020. Yearly increase slows to 6.5% from 7.1%. Core CPI rose 0.3%. Increase in core rate in the past 12 months tapers to 5.7% from 6%. More evidence inflation is easing.
1
Join me and today at noon if you want to ask me anything about my new book, FOR BLOOD AND MONEY.
Quote Tweet
A new book by our managing editor @nathanvardi tells the story of the biotech boom and two of the greatest biotech trades of all time. Join a discussion between him and our biopharma writer @jaimy_lee to tomorrow learn more about biotech investing: trib.al/pdlyzNT
THE GOLDEN AGE OF BIOTECH INVESTING  Jaimy Lee, Health Editor, MarketWatch Nathan Vardi, Managing Editor for Enterprise, MarketWatch  A new book, FOR BLOOD AND MONEY, tells the story of the biotech boom and two of the greatest biotech trades of all time. Jaimy Lee talks to the book's author, MarketWatch Managing Editor Nathan Vardi, about the golden age of biotech investing and whether or not it's over.  WEDNESDAY, JAN. 11, 12 PM EST  REGISTER NOW: barrons.com/live  BARRON'S LIVE MarketWatch
2
Prince Harry is not the only author with a book coming out next week. FOR BLOOD AND MONEY is also on Apple's most anticipated books of 2023 list.
Quote Tweet
Start filling up your TBR with some of the most anticipated books of 2023. Explore buzzy reads in every genre: apple.co/2023NewBooks
Image
1
4
This is a great interview by Laura and I think Martin is the closest parallel to SBF, more than Madoff, Holmes or anyone else.
Quote Tweet
😳 Serving time was “the easy part for me,” says convicted white-collar criminal Martin Shkreli. Here’s why he says awaiting sentencing is probably the hardest thing SBF will ever go through in his life. Full episode: youtu.be/9B13IUpGWqg
Embedded video
2:05
13K views
4
23